Well, Dr. Bennett, if I could ask the question back, has that Institute on Governance report been distributed to the members of this committee? I ask because we were provided with this report in September of last year.
The document that we received is dated April of 2008 and is marked as confidential, and we were assured by Rx&D, the organization that mandated this report, that we would be permitted, if the report were to be made public, to respond to some of the questions, one of which you're presenting today.
The issue of mandate creep is something that is easy to throw out there, but our mandate has not changed: we operate under the Patent Act and we have regulations. The Patent Act has not been changed since 1993; our regulations have not been changed since 1994.
Now, we have a dual mandate. We have both a reporting role and a regulatory role. If you didn't like the regulatory role, you would say that our mandate is mostly reporting; but we do have a double mandate, and one doesn't take precedence over the other. The Patent Act clearly gives us a mandate to regulate the prices of patented medicines.